PTC Therapeutics (PTCT) News Today → Don’t expose yourself to stocks during the week (From DTI) (Ad) Free PTCT Stock Alerts $33.10 -0.94 (-2.76%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 4:30 AM | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Reduce" by BrokeragesMay 17 at 6:20 AM | marketbeat.comBNP Paribas Financial Markets Increases Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)BNP Paribas Financial Markets lifted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 263.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 371,580 shares of the biopharMay 14, 2024 | marketwatch.comPTC Therapeutics Gets FDA Priority Review of Upstaza Gene TherapyMay 14, 2024 | prnewswire.comPTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™May 10, 2024 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Position Trimmed by Russell Investments Group Ltd.Russell Investments Group Ltd. trimmed its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 13.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 191,120 shares of the biopharmaceutical company's stock afMay 9, 2024 | seekingalpha.comPTCT PTC Therapeutics, Inc.May 2, 2024 | prnewswire.comPTC Therapeutics to Participate at Upcoming Investor ConferencesMay 1, 2024 | finance.yahoo.comPTC Therapeutics Stock Sees IBD RS Rating Climb To 72April 29, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Trading 6.1% Higher PTC Therapeutics (NASDAQ:PTCT) Trading Up 6.1%April 29, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Upgraded at Morgan StanleyMorgan Stanley upgraded PTC Therapeutics from an "underweight" rating to an "equal weight" rating and boosted their price objective for the stock from $28.00 to $30.00 in a research note on Monday.April 28, 2024 | finance.yahoo.comIndustry Analysts Just Made A Captivating Upgrade To Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue ForecastsApril 27, 2024 | seekingalpha.comPTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call TranscriptApril 26, 2024 | finance.yahoo.comSector Update: Health Care Stocks Edge Higher Late AfternoonApril 26, 2024 | finance.yahoo.comPTC Therapeutics Inc (PTCT) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ...April 26, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Shares Gap Up Following Better-Than-Expected EarningsPTC Therapeutics (NASDAQ:PTCT) Shares Gap Up on Better-Than-Expected EarningsApril 25, 2024 | investorplace.comPTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024April 25, 2024 | prnewswire.comPTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsApril 23, 2024 | prnewswire.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 23, 2024 | insidertrades.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells 3,361 Shares of StockApril 22, 2024 | marketbeat.comMatthew B. Klein Sells 3,361 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CEO Matthew B. Klein sold 3,361 shares of the firm's stock in a transaction dated Friday, April 19th. The stock was sold at an average price of $24.89, for a total transaction of $83,655.29. Following the completion of the transaction, the chief executive officer now directly owns 225,807 shares in the company, valued at $5,620,336.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.April 21, 2024 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Knights of Columbus Asset Advisors LLCKnights of Columbus Asset Advisors LLC lifted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 104.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,424 shares of the biApril 21, 2024 | investing.comPTC Therapeutics CEO sells shares worth over $19kApril 20, 2024 | insidertrades.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells 787 Shares of StockApril 19, 2024 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Eric Pauwels Sells 787 SharesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CEO Eric Pauwels sold 787 shares of the company's stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $25.14, for a total transaction of $19,785.18. Following the completion of the sale, the chief executive officer now directly owns 67,694 shares in the company, valued at $1,701,827.16. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.April 11, 2024 | finance.yahoo.comPTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial ResultsApril 11, 2024 | prnewswire.comPTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial ResultsApril 5, 2024 | insidertrades.comPTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Sells $14,922.62 in StockApril 1, 2024 | msn.comSolid Biosciences gets FDA rare pediatric disease status for DMD therapyApril 1, 2024 | marketbeat.comVanguard Group Inc. Boosts Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)Vanguard Group Inc. raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 5.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,945,489 shares of the biopharmaceutiMarch 31, 2024 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Bought by Assenagon Asset Management S.A.Assenagon Asset Management S.A. raised its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 366.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 242,661 shares of the biopharmaceuticalMarch 28, 2024 | finance.yahoo.comPTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMAMarch 21, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $35.00 at Jefferies Financial GroupJefferies Financial Group boosted their target price on PTC Therapeutics from $33.00 to $35.00 and gave the stock a "buy" rating in a research report on Wednesday.March 20, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Shares Down 3.7% PTC Therapeutics (NASDAQ:PTCT) Shares Down 3.7%March 19, 2024 | markets.businessinsider.comBuy Rating for PTC Therapeutics Bolstered by Positive Regulatory Prospects and Gene Therapy AdvancesMarch 19, 2024 | markets.businessinsider.comPTC Therapeutics Gains After Announcement Of Key Regulatory UpdatesMarch 19, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Trading Up 3.3%PTC Therapeutics (NASDAQ:PTCT) Trading 3.3% HigherMarch 19, 2024 | finanznachrichten.dePTC Therapeutics, Inc.: PTC Therapeutics Provides Key Regulatory UpdatesMarch 19, 2024 | markets.businessinsider.comPTC Therapeutics Submits BLA To FDA For Upstaza - Quick FactsMarch 19, 2024 | finance.yahoo.comPTC Therapeutics Provides Key Regulatory UpdatesMarch 19, 2024 | marketbeat.comWalleye Capital LLC Has $1.61 Million Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Walleye Capital LLC raised its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 958.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 72,030 shares of the biopharmaceutical company's stock after buying anMarch 16, 2024 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Bought by Citigroup Inc.Citigroup Inc. raised its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 129.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 207,118 shares of the biopharmaceutical company's stock aftMarch 14, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Trading Down 5.9%PTC Therapeutics (NASDAQ:PTCT) Trading Down 5.9%March 12, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Buys 104,024 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Jacobs Levy Equity Management Inc. raised its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 10.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,122,698 shares of the biopharmaceutical company'sMarch 11, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Has $3.36 Million Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)Adage Capital Partners GP L.L.C. decreased its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 77.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 150,000 shares of the biopharmaceutical company'sMarch 8, 2024 | marketbeat.comQ2 2024 EPS Estimates for PTC Therapeutics, Inc. Decreased by Analyst (NASDAQ:PTCT)PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q2 2024 EPS estimates for PTC Therapeutics in a research report issued to clients and investors on Tuesday, March 5th. Leerink Partnrs analyst J. Schwartz now expects that the biopharmMarch 7, 2024 | marketbeat.comSeven Eight Capital LP Purchases Shares of 64,722 PTC Therapeutics, Inc. (NASDAQ:PTCT)Seven Eight Capital LP bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 64,722 shares of the biopharmaceutical company's stock,March 7, 2024 | marketbeat.comFY2024 EPS Estimates for PTC Therapeutics, Inc. Lowered by Cantor Fitzgerald (NASDAQ:PTCT)PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Stock analysts at Cantor Fitzgerald reduced their FY2024 EPS estimates for PTC Therapeutics in a research note issued on Monday, March 4th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will earn ($5.02) pMarch 7, 2024 | markets.businessinsider.comPTC Therapeutics: Navigating Challenges and Pursuing Growth Amidst Regulatory HurdlesMarch 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for PTC Therapeutics Amid Promising Regulatory Progress and Market OpportunityMarch 3, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Shares Gap Down on Analyst DowngradePTC Therapeutics (NASDAQ:PTCT) Shares Gap Down After Analyst Downgrade Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover PTCT Media Mentions By Week PTCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTCT News Sentiment▼0.850.51▲Average Medical News Sentiment PTCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTCT Articles This Week▼44▲PTCT Articles Average Week Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INDV News ACAD News DYN News RYTM News JANX News VERA News GERN News MLTX News BHC News ARVN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTCT) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Presidential candidate you should REALLY be worried aboutStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
